Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dexamethasone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 8/20 | 0.92 |
| ▸ | HIF1A | Q16665 | 9/20 | 0.92 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.92 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.92 |
| ▸ | NFKB1 | P19838 | 4/20 | 0.92 |
| ▸ | PGR | P06401 | 3/20 | 0.92 |
| ▸ | TSHR | P16473 | 2/20 | 0.92 |
| ▸ | AR | P10275 | 2/20 | 0.92 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.92 |
| ▸ | MEN1 | O00255 | 1/20 | 0.92 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.92 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.92 |
| ▸ | APEX1 | P27695 | 1/20 | 0.92 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.92 |
| ▸ | IKBKB | O14920 | 1/20 | 0.92 |
| ▸ | CHUK | O15111 | 1/20 | 0.92 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.92 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.92 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.92 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.92 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Betamethasone SCHEMBL509818 | 1.00 | HIF1A (0.92) | HIF1ANR3C1CYP3A4HSD17B10NFKB1 | |
| Dexamethasone SCHEMBL122397 | 1.00 | HIF1A (0.92) | HIF1ANR3C1CYP3A4HSD17B10NFKB1 | |
| Betamethasone SCHEMBL515750 | 1.00 | HIF1A (0.92) | HIF1ANR3C1CYP3A4HSD17B10NFKB1 | |
| Betamethasone SCHEMBL7521 | 1.00 | HIF1A (0.92) | HIF1ANR3C1CYP3A4HSD17B10NFKB1 | |
| Betamethasone SCHEMBL28843099 | 0.99 | HIF1A (0.90) | HIF1ANR3C1CYP3A4HSD17B10NFKB1 | |
| Betamethasone SCHEMBL4188771 | 0.99 | HIF1A (0.90) | HIF1ANR3C1CYP3A4HSD17B10NFKB1 | |
| Betamethasone SCHEMBL8077644 | 0.98 | HIF1A (0.89) | HIF1ANR3C1CYP3A4HSD17B10NFKB1 | |
| Betamethasone SCHEMBL28161851 | 0.98 | HIF1A (0.89) | HIF1ANR3C1CYP3A4HSD17B10NFKB1 | |
| Dexamethasone SCHEMBL29137991 | 0.97 | HIF1A (0.98) | HIF1ANR3C1CYP3A4HSD17B10NFKB1 | |
| Betamethasone SCHEMBL120210 | 0.96 | NR3C1 (0.84) | HIF1ANR3C1CYP3A4HSD17B10NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2817 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250295608-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING OSTEOARTHRITIS | INSIGNIA PHARMACEUTICALS, LLC (US) | 2025-09-25 | — | — | US | claimed |
| US-20250288599-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING OSTEOARTHRITIS | INSIGNIA PHARMACEUTICALS, LLC (US) | 2025-09-18 | — | — | US | claimed |
| CN-118662425-A | Preparation method of high-drug-loading uniform soluble microneedle based on continuous vacuum casting equipment | 南通微臻医药科技有限公司 | 2024-09-20 | — | — | CN | claimed |
| US-20240189479-A1 | Cardiovascular Prostheses | CORVIVO CARDIOVASCULAR, INC. | 2024-06-13 | — | — | US | claimed |
| CN-115463084-B | Compound oil solution preparation for long-acting analgesia and preparation method thereof | 北京泰德制药股份有限公司 | 2024-05-28 | — | — | CN | claimed |
| EP-3993715-B1 | IMPLANTATION NEEDLE FOR INSERTING A SUBCUTANEOUSLY INSERTABLE ELEMENT INTO A BODY TISSUE | HOFFMANN LA ROCHE (CH) | 2024-04-17 | — | — | EP | claimed |
| EP-4335413-A2 | PROSTHETIC TISSUE VALVES | Cormatrix Cardiovascular, Inc. (US) | 2024-03-13 | — | — | EP | claimed |
| WO-2023212179-A2 | THERAPEUTIC COMPOSITIONS FOR SKIN DISORDERS AND WOUND REPAIR | UNIVERSITY OF MIAMI (US) | 2023-11-02 | — | — | WO | claimed |
| US-20230210868-A1 | Methods of Treatment Using ICAM-Modulating Agents | AVM BIOTECHNOLOGY, LLC (US) | 2023-07-06 | — | — | US | claimed |
| CN-112336688-B | Oil-in-water type compound hydroquinone emulsion as well as preparation method and application thereof | 广东人人康药业有限公司 | 2023-03-17 | — | — | CN | claimed |
| EP-1451577-A2 | SOLUBLE CD40L(CD154) AS A PROGNOSTIC MARKER OF ATHEROSCLEROTIC DISEASES | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2004-09-01 | — | — | EP | claimed |
| WO-2003088811-A2 | GELSOLIN AS A PROGNOSTIC MARKER OF ARTHEROSCLEROTIC DISEASES | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2003-10-30 | — | — | WO | claimed |
| US-20030152566-A1 | Soluble CD40L (CD154) as a prognostic marker of atherosclerotic diseases | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2003-08-14 | — | — | US | claimed |
| WO-2003040691-A2 | SOLUBLE CD40L(CD154) AS A PROGNOSTIC MARKER OF ATHEROSCLEROTIC DISEASES | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2003-05-15 | — | — | WO | claimed |
| WO-2001015744-A9 | SYSTEMIC INFLAMMATORY MARKERS AS DIAGNOSTIC TOOLS IN THE PREVENTION OF ATHEROSCLEROTIC DISEASES | BRIGHAM & WOMENS HOSPITAL (US) | 2002-09-26 | — | — | WO | claimed |
| JP-2001525058-A | — | — | 2001-12-04 | — | — | JP | claimed |
| EP-1003501-A4 | MEANS OF ASCERTAINING AN INDIVIDUAL'S RISK PROFILE FOR ATHEROSCLEROTIC DISEASE | BRIGHAM & WOMENS HOSPITAL (US) | 2001-01-17 | — | — | EP | claimed |
| EP-1003501-A1 | MEANS OF ASCERTAINING AN INDIVIDUAL'S RISK PROFILE FOR ATHEROSCLEROTIC DISEASE | BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2000-05-31 | — | — | EP | claimed |
| WO-1998043630-A1 | MEANS OF ASCERTAINING AN INDIVIDUAL'S RISK PROFILE FOR ATHEROSCLEROTIC DISEASE | BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 1998-10-08 | — | — | WO | claimed |
| WO-1997027862-A1 | SUPPLEMENTATION OF GLUCOCORTICOIDS | BELLARA MEDICAL PRODUCTS LIMITED (AU) | 1997-08-07 | — | — | WO | claimed |